Systematic Serendipity
for Rare Disease

An estimated 400 million people around the world are affected by a rare disease. Of the 8000+ rare diseases that we know of, 95% don’t have any treatment options.

​

Aspire Biosciences wants to change that. Based in Cambridge, within Europe's largest life-sciences cluster, we work tirelessly to give hope to rare disease patients and their loved ones.

 

We find new treatments for unaddressed rare diseases through our innovative methodology called Systematic Serendipity, which creates working partnerships between patient groups and R&D companies.